Low level of DAP-kinase DNA methylation in myelodysplastic syndrome.

Abstract

CHOP-14 will not be answered until the analysis of the completed RICOVER-60 trial (1220 patients), which should be available in summer 2005. Moreover, there are no data on the addition of rituximab to intensified chemotherapy regimens in young high-risk patients, and the respective Mega-CHOEP (CHOP etoposide) trial of the DSHNHL has just started recently… (More)

Topics

3 Figures and Tables

Cite this paper

@article{Brakensiek2004LowLO, title={Low level of DAP-kinase DNA methylation in myelodysplastic syndrome.}, author={Kai Brakensiek and Florian L{\"a}nger and Hans Heinrich Kreipe and Ulrich Lehmann}, journal={Blood}, year={2004}, volume={104 5}, pages={1586-7; author reply 1587-8} }